Journal article
Nonviral Gene Therapy Approaches to Hemophilia
Abstract
The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are …
Authors
Gómez-Vargas A; Hortelano G
Journal
Seminars in Thrombosis and Hemostasis, Vol. 30, No. 02, pp. 197–204
Publisher
Thieme
Publication Date
April 2004
DOI
10.1055/s-2004-825633
ISSN
0094-6176